announces Blackpink

Blackpink Announces New Single From ‘The Album’ – Billboard


Courtesy of YG Entertainment


With just days to go until the release of The Album, Blackpink has served fans a new teaser of what’s to come.

Jennie, Rosé, Jisoo and Lisa tweeted a poster previewing “Lovesick Girls” as a “title” (or main) track from their upcoming debut full-length studio album Sunday night (Sept. 27).

The teaser poster shows the song name and the girls leaning on one another in nighttime lighting, with a reminder of The Album‘s almost here Oct. 2 release date.

Blackpink has already treated fans to two tracks ahead of the album drop, “How You Like That” and the Selena Gomez collaboration “Ice Cream.”

Before The Album is here, the quartet welcomes fans to join them for “Comeback Live,” a live streaming event set to take place Oct. 1 at 9 p.m. ET on VLive.

See the “Lovesick Girls” teaser poster below.

Read More

announces Trump

Trump announces Judge Amy Coney Barrett is his pick for the Supreme Court – The Washington Post

Trump introduced Barrett in a Rose Garden ceremony attended by a who’s who of Republicans and conservative activists, a reminder that shifting the Supreme Court to the ideological right has been a decades-long focus for Republicans.

“Amy Coney Barrett will decide cases based on the text of the Constitution as written,” Trump said, as the nominee stood beside him. “As Amy has said, being a judge takes courage. You are not there to decide cases as you may prefer. You are there to do your duty and to follow the law, wherever it may take you.”

Neither Trump nor Barrett wore face masks as recommended by public health officials to reduce the spread of the coronavirus, and few in the crowd did either. Guests were seated close together, rather than the recommended six feet apart, and hugged and kissed one another.

Trump and Barrett praised Ginsburg as a trailblazer, and Barrett said she would do the job of a justice “mindful of who came before me.”

Their views and backgrounds could not be more different, however, as the deeply conservative Barrett made clear with a tribute to the late Antonin Scalia, the conservative jurist for whom she was a law clerk and who she said was her legal role model.

“I have no illusions that the road ahead of me will be easy, either for the short term or the long haul. I never imagined that I would find myself in this position, but now that I am, I assure you that I will meet the challenge with both humility and courage,” Barrett said, adding that she looked forward to meeting with senators.

The judge for the U.S. Court of Appeals for the 7th Circuit is expected to be confirmed swiftly by the Republican-majority Senate and could be seated before the Nov. 3 election, the resolution of which Trump has predicted could end up before the Supreme Court.

Democrats, with little chance of derailing the nomination, say they are being steamrolled. Some in the party are refusing to meet with Coney Barrett, while liberal activists are pushing Democratic lawmakers for more drastic moves such as boycotting the confirmation hearings.

Senate Republicans were preparing to accelerate the confirmation process as soon as the announcement was made, with Senate Majority Leader Mitch McConnell (R-Ky.) planning to meet with Barrett on Tuesday, according to an aide.

Senate Judiciary Committee Chairman Lindsey O. Graham (R-S.C.) confirmed in an interview with Fox News on Saturday night that the hearings for Barrett will begin Oct. 12 with opening statements, with questions set to take place Oct. 13 and 14. There will be testimony from outside witnesses at some point, he said, and the committee process will begin Oct. 15 — meaning a panel vote on Barrett’s nomination could come as early as Oct. 22 under Judiciary rules.

“I expect they’re going to throw the kitchen sink at us,” Sen. John Barrasso (Wyo.), the No. 3 in Senate GOP leadership, said in an interview Saturday. But he said he was confident Barrett would be confirmed before the election “if everything moves along smoothly.”

The prospect of conservative judges and a shift on the high court helped Trump, with few ideological lodestars, win over skeptical Republicans in 2016, and he has been unapologetic about using this surprise vacancy to further his chances for reelection.

“Fill that seat” has been a featured chant at Trump’s political rallies over the past week, and his campaign is raising money with messages to supporters that tout the president’s Supreme Court pick. Republicans also started selling a T-shirt Saturday that appropriated Ginsburg’s pop-culture-inspired nickname, “Notorious RBG.” The shirts say “Notorious ACB.”

Ginsburg lay in state at the U.S. Capitol this past week — the first woman to be so honored — and is expected be buried alongside her husband, Marty, at Arlington National Cemetery in the coming week.

The election was not mentioned during the White House announcement, nor was abortion, the issue on which many senators of both parties are likely to base their vote on Barrett.

Democratic presidential nominee Joe Biden issued a statement on the nomination that focused on the coronavirus and the future of the Affordable Care Act, which is back before the high court in the term that begins Oct. 5.

“She has a written track record of disagreeing with the U.S. Supreme Court’s decision upholding the Affordable Care Act” in 2012, Biden said, noting that Barrett had also criticized Chief Justice John G. Roberts Jr. for his deciding vote in that case.

The 16 days from Barrett’s nomination to the start of her confirmation hearings would be the shortest in recent memory. Since 1990, it has taken an average of 50 days from a Supreme Court pick’s nomination to the start of his or her confirmation hearings — significantly shortcutting the time available for senators to examine Barrett’s record, read through her writings and to prepare questions for the hearings.

GOP leaders are aiming for a final confirmation vote just days before Election Day, a goal they say is feasible in part because Barrett’s record and background were already scrutinized during her bitter 2017 confirmation to the federal bench.

Democrats cited McConnell’s 2016 refusal to hold hearings for President Barack Obama’s last Supreme Court nominee, Judge Merrick Garland, on the theory that voters in that year’s presidential election should have their say first.

McConnell and Graham have reversed themselves to say that Trump’s confirmation pick should go forward before the election.

In a statement Saturday, Graham pledged to seek “a challenging, fair, and respectful hearing” but did not spell out a timeline.

White House Chief of Staff Mark Meadows declined to predict Saturday whether a pre-election confirmation is likely.

“That would be a discussion for the senators. I would believe that they’re going to try to move through the process and review her credentials in an expeditious manner,” Meadows told reporters at the White House.

“The authority of the chairman to rush this process in a way that he’s determined to do is such a mockery and travesty,” Sen. Richard Blumenthal (D-Conn.), a member of the Judiciary Committee, said in an interview.

Blumenthal has said he does not plan to meet with Barrett, a departure from past confirmations.

Barrett is already well known to Republican senators, many of whom had hoped Trump would pick her for the next vacancy. When Trump said he would consider only women to fill Ginsburg’s seat, Barrett became the automatic favorite.

Trump said he considered five women, but Barrett is the only one he is known to have interviewed in person.

McConnell made known to Trump his preference for Barrett, since his ranks were the most familiar with her. Although her writings on precedent and personal antiabortion views could be a significant obstacle for Sens. Susan Collins (R-Maine) and Lisa Murkowski (R-Alaska) — who support access to abortion — both have said they do not support holding a confirmation vote before the election anyway. That cleared the way for Trump and McConnell to push through the most conservative candidate possible.

As he departed the White House for a Saturday night rally in Pennsylvania, Trump told reporters he did not discuss abortion with Barrett during their interview. “I never discussed that with Amy” and the court itself is “going to have to make that decision,” he said.

At the rally, he said that “most important of all she will defend your God-given rights and freedoms.” People behind Trump wore MAGA hats and MAGA masks and held signs saying “Fill That Seat” and “Peaceful Protester.”

Senators such as Todd C. Young (R-Ind.) have spoken personally with the president to lobby for Barrett, and Sen. Ben Sasse (R-Neb.) has had eight conversations with Trump to push for her as an eventual Supreme Court nominee.

“In the Scalia tradition of originalism and textualism, she’s just got a giant brain,” Sasse, one of Barrett’s most fervent advocates, said in an interview. “So first of all, there’s that half of the equation, or more than half of the equation. But then you combine a giant brain with just three-dimensional humanity.”

Sasse noted that a wide cross-section of Notre Dame faculty — from traditional conservatives to liberal Catholics — have admired Barrett, even if they don’t agree with her jurisprudence.

Sen. Mike Braun (R-Ind.) said it would be a “major disappointment” if Senate Republicans do not confirm Barrett before Election Day. He anticipated that it would only be delayed until after Nov. 3 if there are “some of the antics that were pulled during the Kavanaugh hearing.”

Trump has told allies that Barrett would be a justice in the mold of Scalia, and Scalia’s son, Labor Secretary Eugene Scalia, attended Saturday’s ceremony and a fundraising reception Friday at the Trump International Hotel, where Trump polled supporters on what they thought of his choice.

Although the group expressed strong support for her, it was not unanimous, according to people familiar with the closed-door event, who spoke on the condition of anonymity to describe the confidential discussion.

When Brian Ballard, a top donor and Florida lobbyist, suggested that he liked federal appellate Judge Barbara Lagoa, Trump said that Ballard should tell Lagoa that she would eventually have her time, two people familiar with the comments said.

Lagoa was considered the other front-runner. Although Trump had said he would probably meet with Lagoa when he visited Florida on Thursday and Friday, he told reporters Friday that he had not done so.

Trump has asked outside allies such as Corey Lewandowski and David Bossie to help work on the confirmation on the outside of the White House apparatus, officials said.

Less influential in this year’s discussions was Leonard A. Leo, the powerful Republican activist who originally helped get Barrett on a list of conservative candidates that Trump said he would use to make his court picks, although Leo said he supports the choice.

“In nominating Amy Barrett to the Supreme Court, President Trump has again fulfilled his promise to appoint justices who are not only exceptionally qualified, but willing to bravely stand up for the Constitution as it’s written and not bend to political pressures or personal preferences,” Leo said. “Judge Barrett will be a great role model for future generations seeking to ensure that the rule of law advances the dignity of all people.”

Barrett would join Justices Neil M. Gorsuch and Brett M. Kavanaugh, both in their 50s, as Trump’s choices for the Supreme Court. All could serve for decades, ensuring that Trump’s stamp on the court would last far beyond his presidency, whether he is reelected this year or not.

Youth activists representing the advocacy groups March for Our Lives and Demand Justice drew a massive chalk mural on the street in front of McConnell’s D.C. home.

“Hey Mitch. We Call BS. Let The People Decide,” it reads.

Demand Justice, a liberal group that advocates against conservatives’ stacking of federal courts, also unveiled a new domain name Friday night: The URL opens to a page on the group’s website dedicated to blocking her confirmation.

“Amy Coney Barrett would threaten your health care and your reproductive freedom. We have to stop her,” it says.

Read More

announces resumption

Pac-12 announces resumption of football, basketball & winter sports seasons –

SAN FRANCISCO – The Pac-12 CEO Group announced today that based upon updated Pac-12 COVID-19 Medical Advisory Committee recommendations that take into account material changes to testing capabilities, the prevalence of COVID-19 and cardiac issues, along with updated state and local health official guidance, the Conference will resume its football, basketball and winter sport seasons.  The football season may now commence for those teams that have the necessary state and local health approvals on November 6, men’s and women’s basketball on November 25 consistent with the NCAA’s official start date for these sports, and other winter sports consistent with the NCAA season dates for those sports.  The decision follows a meeting of the CEO Group last week where the Pac-12 COVID-19 Medical Advisory Committee presented its updated health and safety recommendations (available here), along with the CEO Group having reviewed details on the rollout of the previously announced Quidel daily rapid-results testing program.

For universities utilizing daily antigen testing, at least one weekly PCR test will also be administered for each student-athlete, in addition to all positive tests to be confirmed with a PCR test. All testing recommendations will be reviewed and updated as needed on an ongoing basis.

The August 11 decision of the Pac-12 CEO Group to postpone sport competitions was based upon three central concerns cited by the Medical Advisory Committee: consistent testing capabilities across all Pac-12 universities, the prevalence of the virus in Pac-12 communities and nationally, and concerns related to possible cardiac concerns potentially associated with COVID-19.  The decision to resume sport competitions today is based upon updated Medical Advisory Committee recommendations that point to material improvements in each of these three areas, along with updated state and local public health guidance. 

In addition to the consistent access to sufficient testing across all Pac-12 programs, community prevalence has shown continued improvement in the majority of communities across the Pac-12 footprint. To address concerns regarding potential health outcomes related to the virus, each Pac-12 sports medicine group will be implementing cardiac monitoring protocols for all student-athletes with a positive test. The Pac-12 institutions are also participating in a national COVID-19 cardiac registry which will allow for medical practitioners to monitor closely, and gain greater insight into, potential health outcomes in student-athletes.

With respect to football, there was agreement that these advances permitted either a fall or a winter season.  After extensive discussion of the relative merits of the two approaches, a strong preference emerged for a fall season, and the CEOs unanimously agreed to proceed with that schedule.

No fans will be permitted at any sporting competition taking place on Pac-12 campuses.  The decision to not allow fans at competitions will be revisited based upon health and safety considerations in January 2021.

“The health and safety of our student-athletes and all those connected to Pac-12 sports remains our guiding light and number one priority,” said Pac-12 CEO Group Chair and University of Oregon President Michael Schill.  “Our CEO Group has taken a measured and thoughtful approach to today’s decision, including extensive consultation with stakeholders on the evolving information and data related to health and safety.”

“From the beginning of this crisis, our focus has been on following the science, data and counsel of our public health and infectious disease experts,” said Pac-12 Commissioner Larry Scott.  “Our agreement with Quidel to provide daily rapid-results testing has been a game-changer in enabling us to move forward with confidence that we can create a safe environment for our student-athletes while giving them the opportunity to pursue their dreams. At the same time, we will continue to monitor health conditions and data and be ready to adjust as required in the name of the health of all.”

The Pac-12 COVID-19 Medical Advisory Committee concluded in its updated recommendations that “the conditions for the resumption of contact/competition can be met by the institutions when antigen testing is available on each campus. We believe access to near-daily rapid point of care testing for contact sports will significantly improve our ability to prevent transmission of COVID during higher risk of transmission activities and reduce the risk of travel.”

In the sport of football, Pac-12 universities with the necessary public health approvals may commence practice immediately with a seven game Conference-only season to begin on November 6, and the Pac-12 Championship Game on December 18, enabling Pac-12 teams to be considered for selection by the CFP. The football schedule will be released in the coming days.

In the sport of men’s and women’s basketball, the season will begin on the NCAA official start date of November 25.  Further details regarding basketball schedules will be released in the near future.

For the Winter sports of wrestling, women’s gymnastics, and men’s & women’s swimming and diving, each university will determine when practice may commence in accordance with local public health official guidance and the situation on campus. Final competition schedules will be released for those sports at a later date. Fall sports for which post-season championships were postponed by the NCAA until the spring will be conducted starting January 2021, with preparation and practice occurring during the fall as permitted by NCAA rules.

In all cases, competition with non-conference opponents will be contingent upon such non-conference opponents implementing minimum testing protocols in accordance with NCAA and Pac-12 COVID-19 Medical Advisory Committee recommendations.

Read More

announces Samsung

Samsung announces Galaxy Note 20 phones, its best shot at the new iPhones coming this fall – CNBC

The Samsung Galaxy Note 20 Ultra


Samsung on Wednesday announced a bunch of new products, including phones, tablets, a watch and new earbuds. This is typical timing for Samsung, which usually likes to get its best new products out in August before the fall when Apple typically launches its new iPhone and Apple Watch.

Samsung was the largest phone seller in the world until earlier this month, when Canalys analysis said Huawei overtook it by market share. Samsung and Apple dominate sales in the U.S. But these new devices are high-end phones for people willing to spend $999 to $1,299, not mass-market budget phones that help Samsung achieve its huge market share around the world. Still, Samsung’s Note phones are the nicest crop of devices for the year and will compete directly with Apple’s upcoming iPhone 12 phones.

And it’s clear Samsung is going directly after Apple. Apple typically uses its September event to announce its new phones and new Apple Watch, among other things. And Samsung is doing that earlier.

Here’s what you need to know about what Samsung announced.

Galaxy Note 20 and Galaxy Note 20 Ultra

The Samsung Galaxy Note Ultra


Samsung’s Galaxy Note 20 and Galaxy Note 20 Ultra phones are the highlight announcements. The Note phones come with Samsung’s stylus, known as the “S Pen,” and typically pack the highest-end hardware Samsung can cram in a device. Like last year, there’s a more affordable Galaxy Note 20 that starts at $999 and a higher-end Galaxy Note 20 Ultra with a slightly larger and sharper screen, a bigger battery and smoother performance that starts at $1,299.

Both phones include 5G connectivity but, as we’ve reported in the past, there’s still not much of a need to rush out and get a 5G phone right now, since most carriers only offer 5G connections in limited areas. Still, if you’re planning to keep your phone for 3 to 4 years, it’s good future-proofing so you’ll get faster speeds down the line after wireless carriers have built out their 5G networks.

Samsung put a big focus on the cameras on both phones, with support for recording in really high 8K resolution, recording from multiple microphones at the same time for clearer audio and improved pictures. But the cameras are slightly different between the models. The Galaxy Note 20 Ultra has an ultra-wide lens for capturing more of a landscape in each shot, a high resolution 108-megapixel camera for increased detail and a zoom lens that provides up to 50x zoom. The Galaxy Note 20 has a 64-megapixel camera in place of the 108-megapixel on the Ultra and supports up to 30x zoom.

And, like in year’s past, there’s improvements to the S Pen stylus, which slips into the corner of the phone. Gestures now let you control the phone from across the room, so you can close apps, open recent apps, capture the screen and take pictures. It also has improved handwriting recognition, new support for syncing notes across your phone, tablets and computers, and easier annotation in PDF documents.

The Galaxy Note 20 and Galaxy Note 20 Ultra will be available for pre-order on Aug. 6 at 12:01 a.m. ET and will ship by Aug. 21.

Galaxy Z Fold 2

Samsung Galaxy Z Fold 2


Samsung also announced the Galaxy Z Fold 2. It’s the successor to the original Galaxy Fold, which has screen issues just before launch and was delayed months before it finally came to market. The Galaxy Z Fold 2 has a large 6.2-inch screen on the front. When open, it has a large 7.6-inch foldable display that looks a bit more like a tablet. Samsung didn’t discuss pricing but said it will launch in September.

Galaxy Tab 7, Galaxy Watch 3, Galaxy Buds Live

The Samsung Galaxy Tab S7, Galaxy Watch 3, and Galaxy Buds Live


Samsung also announced a bunch of other stuff, including two tablets meant to compete with Apple’s iPad Pro line, including a 12.4-inch Galaxy Tab S7 Plus and an 11-inch Galaxy Tab S7. Both pack 5G connectivity, Google‘s Android operating system, sharp screens and ship with an included stylus that sticks to the back to recharge. The 11-inch model will start at $649, while the larger Tab S7 Plus will start at $849.

Samsung’s new Galaxy Watch 3 and Galaxy Buds Live headphones were also announced. The Galaxy Watch is similar to past models with a rotating bezel that you can use to select apps. Like the Apple Watch, it can detect when you’re working out and automatically log your exercise for you, in case you forget to start it on the device. It can detect blood pressure, too, but only in Samsung’s home country of South Korea since it hasn’t received FDA approval in the U.S. 

The Galaxy Buds Live are similar to Apple’s AirPods Pro. They’re tiny earbuds that charge in their case, but look like little beans that fit right into your ears. They feature noise cancellation, which should help block out background noise while you’re working or walking around town, and you can dial it back if you need to hear what’s going on around you. They’ll cost $169, which is a big discount from the $249 Apple charges for AirPods Pro.

Read More

announces Moderna

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19 – Yahoo Finance

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19.

An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug Administration (FDA) and consultations with Operation Warp Speed over the past several months, the Company has decided to conduct a significantly larger Phase 3 clinical trial, leaving a gap in BARDA funding that will be closed by this contract modification. Under the terms of the revised contract, BARDA is expanding their support of the Company’s late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. The total value of the award is now approximately $955 million.

“We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19.” said Stéphane Bancel, Moderna’s Chief Executive Officer. “Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks.” identifier is NCT04470427.” data-reactid=”27″ type=”text”>The Phase 3 COVE study is being conducted in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and is expected to begin tomorrow, July 27. The Phase 3 study protocol has been reviewed by the U.S. Food and Drug Administration (FDA) and is aligned to recent FDA guidance on clinical trial design for COVID-19 vaccine studies. The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants at the 100 µg dose level in the U.S. The primary endpoint will be the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease (as defined by the need for hospitalization) and prevention of infection by SARS-CoV-2. The identifier is NCT04470427.

Moderna is working closely with Operation Warp Speed and the NIH, including NIAID’s COVID-19 Prevention Trials Network (CoVPN), to conduct the Phase 3 COVE study. Working together with collaborators like NIH, the Company hopes to achieve a shared goal that the participants in the COVE study are representative of the communities at highest risk for COVID-19 and of our diverse society.

strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. Initial funding of $1.3 billion for Moderna to begin producing mRNA-1273 supply at-risk was secured from investors in the Company’s most recent public equity offering in May 2020.” data-reactid=”29″ type=”text”>The Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the Company’s internal U.S. manufacturing site and strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. Initial funding of $1.3 billion for Moderna to begin producing mRNA-1273 supply at-risk was secured from investors in the Company’s most recent public equity offering in May 2020.

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034.

prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from the VRC. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. Both cohorts, healthy adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300), in the Company’s Phase 2 study of mRNA-1273 are fully enrolled. A summary of the company’s work to date on COVID-19 can be found here.” data-reactid=”32″ type=”text”>mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from the VRC. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. Both cohorts, healthy adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300), in the Company’s Phase 2 study of mRNA-1273 are fully enrolled. A summary of the company’s work to date on COVID-19 can be found here.

Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.

The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated manufacturing plant which enables the promise of the technology platform.

nine development candidates in its prophylactic vaccines modality, including:” data-reactid=”40″ type=”text”>Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

  • Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)
  • RSV vaccine for young children (mRNA-1345)
  • Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653)
  • COVID-19 vaccine (mRNA-1273)
  • Influenza H7N9 (mRNA-1851)
  • Cytomegalovirus (CMV) vaccine (mRNA-1647)
  • Zika vaccine (mRNA-1893 with BARDA)
  • Epstein-Barr virus (EBV) vaccine (mRNA-1189)
  • To date, Moderna has demonstrated positive Phase 1 data readouts for eight prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3, CMV, Zika and COVID-19). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.

    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.” data-reactid=”58″ type=”text”>Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past five years. To learn more, visit Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.” data-reactid=”60″ type=”text”>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine against the novel coronavirus, the parameters and timing of the P

    Read More

    announces Reebok

    Reebok announces it will end partnership with CrossFit after CEO’s insensitive George Floyd tweet – Yahoo Sports

    A single tweet from the founder and CEO of CrossFit has prompted Reebok to announce it will end its relationship with the fitness network by the end of the year. Greg Glassman, who founded the business with his wife in 2000, has since apologized.

    The tweet in question came in response to a statement from the director of the Institute for Health Metrics and Evaluation at the University of Washington.

    The statement called racism a public health issue. Glassman replied with a joke about COVID-19, which the IHM has covered since March. Specifically, he called it “FLOYD-19.”

    Glassman followed that up the next day by criticizing the IHM’s advocacy for quarantines and lamenting national riots.

    Your failed model quarantined us and now you’re going to model a solution to racism? George Floyd’s brutal murder sparked riots nationally. Quarantine alone is “accompanied in every age and under all political regimes by an undercurrent of suspicion, distrust, and riots.” Thanks!

    — Greg Glassman (@CrossFitCEO) June 7, 2020

    A tweet equating a response to systemic racism and police brutality to a global pandemic was bound to draw backlash, and that eventually included one of CrossFit’s biggest corporate partners.

    announced to Footwear News on Sunday that it has ended discussions about extending its partnership with CrossFit and will allow its relationship to come to an end this year:” data-reactid=”25″ type=”text”>Reebok announced to Footwear News on Sunday that it has ended discussions about extending its partnership with CrossFit and will allow its relationship to come to an end this year:

    “Our partnership with CrossFit HQ comes to an end later this year. Recently, we have been in discussions regarding a new agreement, however, in light of recent events, we have made the decision to end our partnership with CrossFit HQ,” Reebok said in a statement emailed to FN. “We will fulfill our remaining contractual obligations in 2020. We owe this to the CrossFit Games competitors, fans and the community.”

    The statement continued, “What doesn’t change is our commitment and dedication to CrossFitters and the passionate CrossFit community. We’re so thankful for the strong bonds we’ve created with coaches, box owners and athletes around the world over the past 10 years. We want to especially thank Dave Castro, Nicole Carroll, Andy Stumpf, Steve Weiss and Jimi Letchford, who were instrumental in ensuring Reebok was welcomed by the community, so that we could do our part to help more people improve their lives through fitness.”

    licensing rights — also questioned the tweet or said they would sever ties with CrossFit.” data-reactid=”28″ type=”text”>Reebok wasn’t alone in severing ties with CrossFit, as a number of gyms — which pay Glassman’s company for licensing rights — also questioned the tweet or said they would sever ties with CrossFit.

    posted Glassman’s reply to an email it had sent questioning his response to the pandemic and protests around Floyd’s death. In an unhinged reply, Glassman questioned the writer’s mental health, called her attitude “disgusting” and deemed her “evil” and “a really s—- person.”” data-reactid=”29″ type=”text”>One CrossFit gym announced it would cease its partnership and posted Glassman’s reply to an email it had sent questioning his response to the pandemic and protests around Floyd’s death. In an unhinged reply, Glassman questioned the writer’s mental health, called her attitude “disgusting” and deemed her “evil” and “a really s—- person.”

    Glassman later released a statement via the @CrossFit Twitter account, saying his choice of words was “not racist but a mistake” and calling for racial justice.

    Floyd is a hero in the black community and not just a victim. I should have been sensitive to that and wasn’t. I apologize for that. I was trying to stick it to the @IHME_UW for their invalidated models resulting in needless, economy-wrecking, life-wrecking lockdown,

    — CrossFit (@CrossFit) June 8, 2020

    It’s our hope that his murder catalyzes real change resulting in a level playing field for our black brothers and sisters.

    Please hear me when I say, we stand by our community to fight for justice. I care about you, our community, and I am here for you.”

    — CrossFit (@CrossFit) June 8, 2020

    fired its chief knowledge officer Russell Berger after he called celebrati

    Read More

    announces Colorado

    Colorado announces no new coronavirus-linked deaths for second straight day – Fox News

    Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.

    For the second straight day, Colorado reported no new deaths linked directly to the novel coronavirus, according to official estimates.


    The news comes as deaths from the coronavirus in the Centennial State have continued to decline since peaking in mid-April, the Denver Post reported. 

    Hospitalizations due to COVID-19 are also falling, with some 297 people currently hospitalized in Colorado. The newspaper noted this is the first time since March 27 that less than 300 people in the state have been hospitalized at once due to the coronavirus.

    The news comes after Colorado made a significant change to the way it counts COVID-19 deaths that reduced the statewide figure from more than 1,000 to 878 in mid-May. The change came after Colorado’s Department of Public Health admitted that its COVID-19 death toll was counting those who tested positive for the coronavirus but had died of other causes. The state now separates the two, now listing “deaths among cases” and “deaths due to COVID-19” in separate categories in its official estimates.


    Colorado has reported 26,378 cases of the novel virus, with some 1,181 deaths due to COVID-19, according to the latest estimates. 

    Read More

    announces Microsoft

    Microsoft announces supercomputer with human like artificial intelligence – Yahoo Finance

    Published on 19-May-2020

    Microsoft (MSFT) on Tuesday announced that it has built one of the top five supercomputers in the world designed specifically for OpenAI. The company made the announcement during its Build developers conference, which is being held virtually rather than in person in Seattle where it is usually held each year.

    The supercomputer, Microsoft says, will be used to train OpenAI’s own artificial intelligence models. OpenAI, which was founded in 2015 and received initial funding from the likes of Elon Musk and Sam Altman. Musk has since left the company, while Altman is now its CEO.

    The company is working to create artificial general intelligence, or AI that is capable of outperforming humans, according to the group’s charter. The firm says its main concern is that such technologies benefit all of humanity, while ensuring its power doesn’t become concentrated in the hands of a few.

    The new supercomputer has an incredible 285,000 CPU cores, 10,000 graphics processing units, and 400 gigabits per second of connectivity for each GPU server. While the computer ranks in the top five of the most powerful machines in the world, Microsoft won’t say exactly where it falls on that list.

    #Microsoft #ArtificialIntelligence

    Subscribe to Yahoo Finance:

    About Yahoo Finance:

    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:

    Get the latest news:

    Find Yahoo Finance on Facebook:

    Follow Yahoo Finance on Twitter:

    Follow Yahoo Finance on Instagram:

    Read More

    announces Samsung

    Samsung announces 50-megapixel camera sensor with faster autofocus – The Verge

    Samsung has announced a new 50-megapixel camera sensor called the ISOCELL GN1. It’s Samsung’s first sensor to include both dual-pixel autofocus and Tetracell pixel-binning, which the company says should offer a combination of fast performance and good low-light image quality.

    The pixel size is 1.2μm, closer to what you’d find on a conventional phone camera sensor than the high-resolution chips that’ve become increasingly popular over the past year-plus. The obvious competitor is Sony’s new IMX689 sensor, featured in phones like the Oppo Find X2 Pro, which has 48 megapixels at 1.22μm. By default, Samsung’s sensor will take 12.5-megapixel photos with four pixels binned into one.

    The addition of dual-pixel phase-detection autofocus is noteworthy because Samsung had a recent high-profile failure in that area. The Galaxy S20 Ultra, which used a 108-megapixel sensor without dual-pixel tech, suffered from poor autofocus performance; Samsung said it would issue a fix, though we haven’t been able to test for improvements yet.

    In any case, the combination of high resolution and fast autofocus speed is clearly Samsung’s priority with the ISOCELL GN1. The company says the sensor entered mass production this month, so it shouldn’t be too long before it shows up in phones.

    Read More

    announces SoftBank

    SoftBank announces that Jack Ma will leave its board ahead of earnings report – CNN

    Hong Kong (CNN Business)SoftBank lost a major name from its board and confirmed historic losses on Monday — signs of turmoil at the Japanese conglomerate after it was battered by the coronavirus pandemic and a series of tech bets gone bad.

    Hours before SoftBank reported a record annual operating loss of 1.36 trillion yen ($12.7 billion) — the worst in at least 20 years, according to the data provider Refinitiv — it announced that Alibaba (BABA) founder Jack Ma would resign from its board. Ma, who is still a director of the Chinese e-commerce company, had held the position for nearly 13 years.
    He’s the latest noteworthy board member to leave, after billionaire and Fast Retailing (FRCOF) founder Tadashi Yanai’s departure at the end of last year.
    Ma’s exit is particularly noteworthy because of his closeness to SoftBank founder and CEO Masayoshi Son. Son invested $20 million in Alibaba in 2000, a bet that was worth $60 billion when Alibaba went public in 2014.
    SoftBank did not explain the reasoning behind Ma’s departure. But the company has been taking dramatic measures to shore up its finances, including a plan to sell $41 billion in assets.
    During the earnings presentation Monday, Son revealed that the company had secured $11.5 billion in funding by doing deals that allow SoftBank to sell Alibaba stock in the future.
    SoftBank’s 25.1% stake in the company is currently worth more than $133 billion.
    It’s been a tumultuous time for SoftBank. The sweeping, worldwide restrictions on work and travel caused by the coronavirus pandemic have walloped the company’s investment portfolio.
    Some of Son’s major tech investments, meanwhile, faced rough receptions on Wall Street long before the outbreak. The losses that SoftBank reported Monday were in line with its own recent forecasts and driven almost entirely by SoftBank’s Vision Fund, the $100 billion tech fund steered by Son.
    SoftBank said the Vision Fund and affiliated funds suffered operating losses of 1.9 trillion ($17.7 billion) for the fiscal year that ended in March. The values of Uber (UBER), WeWork and other portfolio companies fell significantly in the three months to March “primarily due to the impact” of the virus, the company said.
    “If the pandemic continues, the company expects that uncertainty in its investment businesses will remain over the next fiscal year,” SoftBank added.
    Son is trying to right the ship. In March, the company made the surprise announcement that it would sell assets to buy back shares and reduce the company’s heavy debt load.
    The Japanese company on Monday also said it is buying back up to 500 billion yen ($4.7 billion) worth of shares over the next year, the second share purchase of this size since March. More buybacks are likely on the way: The company has said it wants to repurchase up to 2 trillion Japanese yen ($18 billion) in stock.
    Shares in SoftBank closed up 1% in Tokyo, outperforming the broader Nikkei 225 (N225), which ended the day 0.5% higher. The stock has lost 21% since its most recent peak last July.

    Read More